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Abstract 28 
 29 
Objective Patterns of benzodiazepine (BZD) use and long-term use among young adults are not well 30 
known. Our aim was to study trends in BZD use and long-term use among 18–25-year-old young 31 
adults by gender and active substance in a nationwide retrospective longitudinal register-based 32 
setting.  33 
Methods All Finns aged 18–25 years with reimbursed purchases of BZDs in 2006–2014 recorded to 34 
the Finnish Prescription Register were included. Annual prevalence rates of BZD use and long-term 35 
use among young adults were reported overall, and according to gender, drug group (anxiolytic or 36 
hypnotic) and active substance. Long-term use of BZDs was defined as purchasing ≥ 180 Defined 37 
Daily Doses (DDDs) in at least two drug purchases during a calendar year.  38 
Results Overall prevalence of BZD use among young adults decreased from 24.0 to 18.8 per 1000 39 
inhabitants in 2006–2014. Prevalence of long-term use decreased from 5.5 to 3.3 per 1000 inhabitants. 40 
Overall BZD use was higher among females, whereas long-term use was more common among males. 41 
Use of anxiolytics was more common than use of hypnotics. Oxazepam, alprazolam, zopiclone and 42 
zolpidem were the most used BZDs, whereas alprazolam and clonazepam were the substances with 43 
most long-term use. The use and long-term use of BZDs have decreased annually since 2008 among 44 
Finnish young adults. Further research is needed to investigate the reasons behind the decline. 45 
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Introduction 57 
Young adulthood is a developmentally critical phase associated with several challenges, such as 58 
achievement of independence, identity formation and important decision making for the future (Patel 59 
et al. 2007). Many mental disorders become prevalent during adolescence and young adulthood, and 60 
approximately three fourth of lifetime psychiatric disorders have emerged by the age of 24 (Kessler 61 
et al.2005). Studies have shown that psychotropic drug use has increased among adolescents and 62 
young adults in recent decades (Autti-Rämö et al 2009; Hsia et al 2009, Hartz et al. 2016). However, 63 
most of the pharmacoepidemiological research assessing the use and long-term use of BZDs has 64 
focused on adult population or the aged (Kurko et al. 2016) who consume BZDs more commonly 65 
than younger age groups and are at an increased risk for adverse effects associated with regular BZD 66 
use (Barker et al. 2004, Glass et al. 2005)  67 
 68 
Previous studies on BZD use among young adults have concerned specific populations, such as 69 
patients with substance use disorders, or focus on abuse of BZDs (McCabe et al 2005, Kornor et al. 70 
2010, Riska et al. 2014). In studies assessing BZD use in general populations, young adults have been 71 
included as one of the age-groups (Lagnaoui et al 2004, Cunningham et al. 2010, Hollingworth et al. 72 
2010, Nordfjaern et al 2012, Olfson et al. 2015). In United States, the prevalence of BZD use was 2.6 73 
% and 0.4 % for long-term use among young adults (aged 18–35) (Olfson et al. 2015). In a Norwegian 74 
study cohort, 4 % of young adults aged 18–25 years had received a prescription for BZDs, 1 % used 75 
BZDs at least 180 DDD per year, and 0.5 % were defined as chronic users (Nordfjaern et al. 2012). 76 
Among Taiwanese incident BZD users (aged 16–19), 5 % were long-term users (Yeh et al. 2011)  77 
 78 
There is limited population-based knowledge on the use of BZDs among young people due to the fact 79 
that most research has been conducted either among adults in general or among older adults (Kurko 80 
et al 2016). The objective of this study was to assess nationwide trends in the prevalence of BZD use 81 
and long-term use among young adults 18–25 years of age over a nine-year period of 2006–2014 82 
overall and according to gender and active substance.  83 
Materials and Methods 84 
 85 
Data sources 86 
 87 
This nationwide, retrospective register-based study is based on data from the Finnish Prescription 88 
Register of the Social Insurance Institution of Finland. The Finnish National Health Insurance covers 89 
all Finnish residents. The Prescription Register contains individual level information on all 90 
reimbursed drug purchases dispensed to Finnish residents in outpatient care. In the database, all drugs 91 
are classified according to the World Health Organization’s, (WHO 2017) Anatomical Therapeutic 92 
Chemical (ATC) classification system. The data compiled for the present study contains information 93 
on each patient’s personal identifier based on person’s personal identification number in encrypted 94 
form, age at the end of the year, gender, ATC code of the dispensed drug, dispensing date, number of 95 
dispensed packages and number of defined daily doses (DDDs) dispensed. According to Finnish 96 
legislation, ethical approval was not required to conduct this register-based study with anonymized 97 
patient data. Permission to use data was given by the register holder, the Social Insurance Institution 98 
of Finland. 99 
 100 
 101 
The BZDs included in this study are presented in supplementary table 1.  These were anti-epileptic 102 
clonazepam (ATC-code N03AE01), traditional BZD anxiolytics (N05BA), traditional BZD 103 
hypnotics (N05CD), BZD related drugs, also called z-hypnotics (N05CF) and combination of 104 
chlordiazepoxide and amitriptyline (N06CA01). Purchases of orally administered dosage forms were 105 
included in this study with the exception of oral suspensions.  106 
 107 
The study population consisted of all 18–25-year-old young adults with at least one reimbursed 108 
purchase of BZD between 1 January 2006 and 31 December 2014. Young adults were selected as a 109 
study population because the majority (94.3%, n=68 167) of 0–25-year-old BZD users (n=72 266) 110 
were 18–25-year-old young adults (Figure 1), and the definition for DDD by WHO (2016) concerns 111 
only adults. Person’s age was calculated at the end of each calendar year. Numbers of BZD users, 112 
dispensed prescriptions and persons aged 0–25 covered by National Health Insurance in 2014 are 113 
presented in Figure 1.  114 
 115 
 116 
 117 
Study variable construction  118 
 119 
Anti-epileptic clonazepam was included in this study when used for other than epileptic indications, 120 
i.e. when purchased without special reimbursement for epilepsy. In the Finnish system, patients’ 121 
entitlement for special reimbursement is based on doctor’s certificate fulfilling certain diagnosis 122 
criteria. These purchases with special reimbursements are distinguished in a register with special 123 
coding. In the non-epileptic indications, the dosing is lower compared to dosing for epilepsy (8mg). 124 
The dosage of 1mg was used as the defined daily dose for clonazepam use based on the literature and 125 
clinical experience (White 2009, Drug and Alcohol Services 2012, Ashton 2013). 126 
 127 
BZDs in ATC-classes N03AE01, N05BA, N06CA01 were classified as anxiolytics, and drugs in 128 
ATC-classes N05CD and N05CF as hypnotics. 129 
 130 
 131 
Reimbursed drug purchase of BZDs was used as a proxy for BZD use (Haukka et al 2007). Long-132 
term use of BZDs was defined as at least 180 DDD purchases of BZDs and two or more drug 133 
purchases during a calendar year corresponding to six months’ use. This definition of six months’ use 134 
was based on the WHO’s recommendation as the definition for long-term use and a systematic review 135 
concerning long-term use BZD use (World Health Organization 1996; Kurko et al 2015). Drug 136 
consumption of BZDs per patient per year was calculated by using DDDs recommended by WHO 137 
(2016). DDDs of each patient’s drug purchases were combined according to the patient’s personal 138 
identifier.  139 
 140 
One-year prevalence of BZD use and long-term BZD use were assessed overall and according to 141 
gender, drug group (anxiolytic or hypnotic, based on the ATC-classification) and active substance 142 
during 2006–2014. Prevalence rates (number of users per 1000 inhabitants) were calculated according 143 
to the number of the same age Finnish population.  144 
 145 
Statistical analysis 146 
While this study concerns a whole population, data were analyzed with descriptive statistical 147 
methods. Binomial distribution was used to compare changes in prevalence rates between 2006 and 148 
2014. For these prevalence rates, the 95% confidence intervals were calculated. The overall yearly 149 
trends of each studied drug were assessed by comparing these confidence intervals. If the confidence 150 
intervals were not overlapping, the trend during the assessed period was considered to be statistically 151 
significantly changed.  Descriptive data analyses were performed using statistical software IBM SPSS 152 
Statistics version 22.0 and binomial distribution was tested by R version 3.1.3.2015.  153 
 154 
 155 
Results 156 
Overall prevalence of BZD use among young adults decreased statistically significantly, by 21.5% 157 
from 24.0 to 18.8 / 1000 inhabitants over a nine-year period (Figure 2). The annual prevalence of 158 
BZD use increased between 2006 and 2008, the highest prevalence (28.6 / 1000 inhabitants) being 159 
observed in 2008. The use of BZDs was more common in females than males during the study period. 160 
In 2014, prevalence of BZD use among females was 22.8 / 1000 inhabitants and among males 15.1 / 161 
1000 inhabitants.  162 
 163 
Overall prevalence of long-term use of BZDs among 18–25-year-old Finns decreased statistically 164 
significantly, by 39.8% from 5.5 to 3.3 per 1000 inhabitants during 2006–2014. In 2014, the last 165 
studied year, 17.5% of all 18–25-year-old BZD users were defined as long-term users. The prevalence 166 
of long-term use was higher among males than females during the entire study period. 167 
 168 
Use of anxiolytic BZDs was more common than use of hypnotics among Finnish young adults (Figure 169 
3). The overall prevalence of anxiolytic use decreased 20.6%, from 15.2 to 12.1 / 1000 inhabitants 170 
during the study period. The use of hypnotics decreased from 12.5 to 8.5 / 1000 inhabitants, 31.8% 171 
between 2006 and 2014. Long-term use of anxiolytics was more common than long-term use of 172 
hypnotics among young adults during the study period. In 2014, the prevalence of long-term use of 173 
anxiolytics was 2.6 / 1000 inhabitants and hypnotics 0.7 / 1000 inhabitants. Both long-term use of 174 
anxiolytics and long-term use of hypnotics decreased during 2006–2014.  175 
 176 
Oxazepam and alprazolam were the most commonly used anxiolytics. The most commonly used 177 
hypnotics were z-drugs zopiclone and zolpidem. Over the nine-year study period, there was a decline 178 
in the use of almost every studied substance. Alprazolam use decreased the most (53.5%) between 179 
2006 and 2014. Only the prevalence of oxazepam use increased by 17.4%, from 5.3 in 2006 to 6.2 180 
per 1000 inhabitants in 2014. Use of diazepam and clonazepam was lower than that of oxazepam and 181 
alprazolam. During the study period, prevalence of diazepam use ranged between 2.0 and 3.4 / 1000 182 
inhabitants, while clonazepam use ranged between 1.6 and 2.3 / 1000 inhabitants, respectively. 183 
 184 
Long-term use of BZDs was relatively low among young adults during the study period. The highest 185 
prevalence of long-term use was observed in alprazolam users during 2006–2009 and in clonazepam 186 
users during 2010–2014. The substance-level prevalence of long-term use decreased in users of all 187 
BZD substances between 2006 and 2014. The decline of long-term use was most significant in 188 
diazepam (58.7 %) and alprazolam (57.9 %) users. Compared to other BZDs, long-term use was more 189 
prevalent among subjects using diazepam and clonazepam. The relative proportions of long-term use 190 
among diazepam and clonazepam users were higher compared to other BZDs. More than half (59.9–191 
64.6 %) of clonazepam users were long-term users during 2006–2014. Corresponding proportions 192 
were 24.9–37.5% among diazepam users and 26.8–32.3% among alprazolam users during the study 193 
period. 194 
 195 
 196 
 197 
Discussion 198 
To our best knowledge, the present study is the first nationwide register-based study focusing on use 199 
and long-term use of BZDs among young adults. Therefore, the present study offers clinically 200 
significant new information on BZD use and long-term use of this less studied user group. We found 201 
a decreasing trend of both BZD use and long-term use among Finnish young adults during the 202 
investigated nine-year study period. The overall prevalence of BZD use decreased by one fifth and 203 
long-term use of BZDs decreased by over one third between 2006 and 2014. Overall BZD use was 204 
more common among females, whereas long-term use was more common among males. The four 205 
most commonly used BZDs among young adults were oxazepam, alprazolam, zopiclone and 206 
zolpidem. Oxazepam was the only substance with increased use between 2006 and 2014. Alprazolam 207 
and clonazepam were the substances mostly used for long-term. 208 
 209 
This study was based on data from the Finnish Prescription Register covering all reimbursed BZD 210 
purchases in Finland among whole population during the investigated period. Key strengths of this 211 
study are the nationwide data and a long nine-year study period. Completeness and accuracy of 212 
records in The Finnish Prescription Register is high.  213 
 214 
Drug purchase was used as a proxy for BZD use, because there is concordance between prescription 215 
database information and self-reported BZD use (Haukka et al 2007). However, this study may 216 
underestimate the total BZD use among young adults in Finland. The Finnish Prescription Register 217 
does not record non-reimbursed drug purchases, inpatients’ drug use or illegal drug use (Furu et al 218 
2010). Moreover, some diazepam and oxazepam purchases in small package sizes are not recorded 219 
in the Prescription Register, as they are not usually reimbursable. The coverage of the register was 220 
76–90% annually compared to wholesale data of BZD provided by the Finnish Medical Agency 221 
(2017). Information on patient’s diagnosis or severity of psychiatric condition is not included in the 222 
Prescription Register.  223 
 224 
Previous studies on BZD use and long-term use have varied considerably in terms of definition for 225 
long-term use, time-period of the study and age group making it difficult to compare the prevalence 226 
rates between studies. There may also be differences in treatment practices between countries. 227 
However, prevalence of BZD use (1.9 %) among Finnish young adults in 2014 was similar to that 228 
reported in France (1.8 %) but lower than reported in studies in the U.S. (2.6 %), Norway (4.0 %) and 229 
Taiwan (6.7 %) (Lagnaoui et al 2004, Yeh et al. 2011,Nordfjaern et al. 2012, Olfson et al. 2015). 230 
Long-term use of BZDs (0.3 %) by Finnish young adults was slightly less common than that reported 231 
among U.S. young adults (0.4 %) in 2008 (Olfson et al. 2015), and among a sample of French young 232 
adults (0.6 %) in 2001 (Lagnaoui et al. 2004). Further, the prevalence of long-term use in Finland 233 
was lower than that observed in a Norwegian study cohort (1 %) during 2004–2008 (Nordfjaern 234 
2012), and among Taiwanese incident BZD users (5 %) in 2001–2005 (Yeh et al 2011). 235 
  236 
It was not possible to include assessment of indications of BZD prescriptions in the present study. 237 
However, results showed that BZDs classified as anxiolytics were more commonly used than 238 
hypnotics, which may suggest that BZDs are more often used in anxiety than sleep disorders among 239 
young adults. At a substance-level, decreasing trend was observed among almost all BZDs except 240 
oxazepam, which was the only substance with increased use. In the last studied year, oxazepam was 241 
the most commonly used BZD among Finnish young adults. Increased use of oxazepam may be due 242 
to its lower abuse liability (Griffiths et al 1984). This study found that long-term use among oxazepam 243 
users was relatively uncommon. However, a recent study showed that oxazepam users were more 244 
prone to dose escalation compared with diazepam users (Tvete et al 2016). Despite the decreasing 245 
trend of long-term use overall and at a substance-level, long-term use was common among users of 246 
high or medium potency BZDs including clonazepam, diazepam and alprazolam. In this study, a 247 
majority of all clonazepam users used the substance for long-term. Similarly, a recent study found 248 
that clonazepam use is often associated with dose escalation (Alessi-Severini et al. 2016). On the 249 
other hand, in the study of Cloos et al. (2015), clonazepam was associated with a lower risk for high-250 
dose use compared to hypnotics and anxiolytics alprazolam and prazepam, which were associated 251 
with the highest risk for high-dose use. 252 
 253 
The observed gender difference in overall BZD use is consistent with other studies showing that use 254 
of BZDs is more common among females than males (Petitjean et al. 2007, Lagnaoui et al 2004, 255 
Cunningham et al. 2010, Olfson et al 2015). The higher prevalence of anxiety and sleep disorders in 256 
females during young adulthood partly explains this finding (Wittchen et al. 1998, Suvisaari et al. 257 
2009). Yet, in our study, long-term use of BZDs was more prevalent in males than females. This 258 
could be partly explained by the previous finding reporting non-medical, e.g. self-reported possible 259 
abuse or misuse, use of anxiolytics and hypnotics in adolescence to be significantly more common in 260 
males than females in Finland compared to many other European countries (Kokkevi et al 2008). 261 
However, our study did not assess the possible abuse of BZDs. 262 
 263 
Decreasing trend in BZD use found in this study suggests that prescribing patterns of BZDs have 264 
changed during recent years. Similar decreasing trend of BZD utilization has also been observed in 265 
the entire Finnish population (Saastamoinen et al. 2016). National guidelines on rational BZD 266 
prescribing recommend to restricting the length of BZD treatment to some weeks (National 267 
Supervisory Authority for Health and Welfare 2015, Working Group set up by the Finnish Medical 268 
Society Duodecmin and the Finnish Sleep Research Society 2017). However, we found that nearly 269 
one out of five young adult BZD users could be defined as a long-term user. Decreasing trend of long-270 
term BZD use among young adults raises questions about the factors associated with decreased use. 271 
It is probable that a part of BZD use has been replaced by other pharmaceutical use or psychosocial 272 
treatments. During recent years, mental health services among adolescents and young adults have 273 
increased, which reflects the enhanced recognition of the treatment need, but may also suggest that 274 
stigma associated with mental health service use has decreased (Pylkkänen and Laukkanen 2011). 275 
Availability of mental health services may have improved, and low threshold online therapies are 276 
available, too (Stenberg et al 2016).  277 
 278 
Based on the findings of this study we suggest that patterns of BZD long-term use among young 279 
people need more research. Long-term treatment with BZDs can be considered medically justified 280 
for some patients. Therefore, it would be of importance to identify specific patient groups, which 281 
would benefit from long-term BZD treatment. However, equally important would be to recognize 282 
those patients who may experience harm of BZD use.  283 
 284 
In conclusion, both overall use and long-term use of BZDs have decreased annually since the year 285 
2008 among Finnish young adults. Decreasing use may be the consequence of increased awareness 286 
of problems related to long-term BZD use and recommendations introduced to rationalize the use of 287 
BZDs. Further research is needed to identify factors associated with the decline in BZD use among 288 
young adults. 289 
 290 
 291 
Clinical Significance 292 
In this first nationwide study on BZD use and long-term use focusing on young adults, we found a 293 
declining trend in use and long-term BZD use. Despite this decline, still a nearly one out of five 294 
young adult BZD users could be defined as a long-term user and part of this long-term use may also 295 
be inappropriate. Our findings urge physicians to pay more attention to BZD prescribing and 296 
monitoring for young men who are especially prone to long-term use. In addition, special concern 297 
regarding the prescription practices of high potency BZDs alprazolam and clonazepam is needed, as 298 
these substances were most commonly used for long-term.   299 
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